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Background: Diabetes mellitus is associated with a high risk of cardiovascular disease. Carotid 
intima-media thickness (CIMT) is increasingly used as a surrogate marker for atherosclerosis. 
Its use relies on its ability to predict future clinical cardiovascular end points.
Methods: This review examines the evidence linking CIMT as a surrogate marker of vascular 
complications in people with type 1 and type 2 diabetes. We have also reviewed the various 
treatment strategies which have been shown to influence CIMT.
Conclusions: CIMT measurement is an effective, noninvasive tool which can assist in 
  identifying people with diabetes who are at higher risk of developing microvascular and 
macrovascular complications. It may also help to evaluate the effectiveness of various treatment 
strategies used to treat people with diabetes.
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Cardiovascular disease in diabetes
Diabetes mellitus is associated with a high risk of cardiovascular disease (CVD) which 
is the most common cause of mortality in people with diabetes.1,2 CVD accounts for 
more than 80% of deaths in people with diabetes.3,4 A two- to fourfold increased risk 
of CVD in people with diabetes compared with the background population has been 
reported by various research groups.5,6
The risk of stroke is increased 150% to 400% in people with diabetes.7–9 In the 
  Multiple Risk Factor Intervention Trial (MRFIT), people taking medications for 
diabetes were three times as likely to develop cerebrovascular disease compared with 
those not receiving medications for diabetes.5 In type 1 diabetes, the prevalence of cere-
brovascular disease has varied from 4% to 21% depending on the duration of diabetes 
and the population studied10–13 and was found to confer an increased risk of stroke 
(odds ratio 11.6; 95% confidence interval [CI]: 1.2–115.2) in a study of 201 people 
younger than 55 years who developed a stroke due to cerebral infarction.14
Diabetes is also associated with increased incidence and extent of peripheral   arterial 
disease.15 Thus, not only does atherosclerosis develop at a younger age in people 
with diabetes, it is also more diffuse and severe than that found in people without 
diabetes. People with diabetes have a two- to fourfold increased risk of peripheral 
arterial disease.16
Ultrasonographic assessment of endothelial function of brachial artery 
  flow-mediated dilatation and evaluation of carotid intima-media thickness (CIMT) 
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Endothelial function and CVD
Endothelial dysfunction precedes the development of 
atherosclerosis and is believed to play a central role in its 
pathophysiology. Ludmer and colleagues first demonstrated 
impaired endothelial-dependent vasodilatation in the pres-
ence of atherosclerosis.17 Endothelial dysfunction in the 
peripheral vessels are modestly correlated with the endothe-
lial function in the coronary vessels.18,19
Flow-mediated dilatation in response to postocclusive 
reactive hyperemia has been used to noninvasively assess 
endothelial function in the peripheral vascular system.20 
Brachial flow-mediated dilation (FMD) has been found to 
be inversely associated with CIMT.21–23 In the Cardiovascular 
Risk in Young Finns Study, FMD and CIMT were measured 
in 2109 healthy people aged 20 to 39 years.21 Individuals 
were classified into subgroups as those with impaired, 
intermediate, and enhanced FMD if the FMD was ,10th 
percentile, between 10th to 90th percentile, and .90th 
percentile, respectively. The number of cardiovascular risk 
factors was correlated with increased CIMT in those indi-
viduals with impaired or intermediate FMD, but not in those 
with enhanced FMD, which suggests a crucial link between 
CIMT and endothelial dysfunction, with the latter appearing 
to be essential for cardiovascular risk factors to be able to 
contribute to atherosclerosis in the arterial wall.
CIMT
CIMT is the area of tissue starting at the luminal edge of the 
artery and ending at the boundary between the media and the 
adventitia (Figure 1).24 It is measured using B-mode ultra-
sound as the composite thickness of the intima and media. 
The ‘double-line pattern’ is thus the distance between the 
two echogenic lines that represent the lumen–intima inter-
face and the media–adventitia interface. CIMT in healthy 
middle-aged adults measures 0.6 to 0.7 mm and greater than 
1.20 mm is considered abnormal.25 CIMT is age-dependent 
and increases at a rate of 0.005 to 0.010 mm/year.26 Thus, in 
younger individuals, a CIMT of greater than 1.00 mm would 
be considered abnormal.27
Iglesias del Sol and colleagues measured the CIMT at the 
common carotid, bifurcation, internal carotid, and combined 
CIMT and found that the area under the receiver operator 
characteristic (ROC) curves, as a predictor of coronary artery 
disease, for these segments were 0.67 (95% CI: 0.61–0.73), 
0.69 (0.63–0.75), 0.67 (0.61–0.73), and 0.67 (0.61–0.73), 
respectively.28 Thus the authors concluded that all the mea-
surement sites had the same ability to predict future cardio-
vascular events.
Limitations of CIMT measurement
There is no standardized protocol for measurement of CIMT. 
This can result in inaccurate measurements of the progression 
or regression of CIMT during the follow up studies or in the 
assessment of any therapeutic interevention on the measured 
CIMT. Since the implementation of the edge detection soft-
ware there has been improved reproducibility and reduced 
interobserever variation.29
Different portions of the carotid artery have been used 
to measure the CIMT, common carotid, bifurcation, internal 
carotid, and combined CIMT which may influence the value 
of the measured CIMT. However in the study by Iglesias 
del Sol and colleagues CIMT was measured at the common 
carotid, bifurcation, internal carotid, and combined CIMT 
and they found that all the measurement sites had the same 
ability to predict future cardiovascular events.28
Measurement of CIMT involves a combined measure 
of the intimal and medial layer of the arterial wall, whereas 
the atherosclerotic process is restricted in the intimal layer, 
particularly in its early phase of atherosclerosis. Further-
more, CIMT is only an indirect assessment of the possible 
atherosclerotic burden in the coronary artereries which is 
the commonest cause of cardiovascular death. In a system-
atic review, Bots and colleagues reviewed 34 studies on the 
relationship of CIMT to coronary atherosclerosis. Thirty 
of these studies showed a modest positive relationship, the 
magnitude of which was similar to that found in autopsy 
studies. The modest relationship between CIMT and coronary 
Figure 1 Carotid intima-media thickness measured at the far wall of the common 
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atherosclerosis most likely reflects variability in atheroscle-
rosis development between the vascular beds rather than 
limitations of CIMT measurements.30
Lastly, measured CIMT is not only a reflection of the 
atherosclerotic burden in the carotid arteies but also reflects 
age-related changes, and it is imperative that the age of an 
individual is taken into account when CIMT is measured.
CIMT – ultrasound vs histology
Ultrasonographic measurements of CIMT compared with 
histological measurements at the far-wall have been found 
to provide an accurate estimation of the IMT.31–33 Pignoli and 
colleagues compared pathological findings in vitro or in situ 
at autopsy with ultrasonographic measurement of intima-
media thickness (IMT) of the aorta and the common carotid 
arteries.34 The authors found an error of less than 20% for 
measurements in three-quarters of normal and pathological 
aortic walls. In addition, no significant difference was found 
between the ultrasonographic measurement in the common 
carotid arteries evaluated in vitro and that determined by this 
method in vivo in young subjects indicating that ultrasonog-
raphy represents a useful approach for the measurement of 
IMT in human arteries in vivo.
CIMT and CVD
CIMT is a surrogate marker of atherosclerosis and provides 
a noninvasive method for the risk assessment of CVD.35–38 
It is a strong predictor of future cardiovascular events and is 
associated with conventional markers of cardiovascular risk 
such as age, diabetes and serum cholesterol.39,40
CIMT is a well-established index of atherosclerosis 
that correlates with prevalent and incident coronary artery 
disease41,42 and stroke.43,44 Studies have shown a relation-
ship between atherosclerosis in the carotid and coronary 
arteries.45,46 Furthermore, statistically significant correlations 
(range 0.3–0.5) between CIMT and coronary atherosclerosis, 
the latter based on a coronary angiogram, coronary calcium 
studies, or intravascular ultrasound, have been noted.30,47,48
CIMT is associated with cardiovascular risk factors49 
and both prevalent and incident coronary artery disease and 
stroke.41,44,50,51 Furthermore, the progression of CIMT is influ-
enced by cardiovascular risk factors and is directly related to 
the risk of future cardiovascular events.48,52 CIMT has therefore 
become a valuable research tool in clinical trials in the assess-
ment of therapeutic agents directed against atherosclerosis. 
Thus, on account of these characteristics, CIMT has been used 
as an intermediate end point to assess the therapeutic efficacy 
of various interventions in a number of clinical studies.53
In a meta-analysis of 37197 individuals followed-up for 
a mean duration of 5.5 years, Lorenz and colleagues found 
that a 0.1 mm absolute difference in CIMT was associ-
ated with a relative risk of myocardial infarction of 1.15 
(95% CI: 1.12–1.17) and a relative risk of stroke of 1.18 
(95% CI: 1.16–1.21).54
Studies have also demonstrated association between 
cardiovascular risk and increased CIMT in people with type 
1 diabetes.55–57
In the recent Multi-Ethnic Study of Atherosclerosis 
(MESA), coronary artery calcium (CAC) scoring was 
  compared to CIMT in predicting CVD incidence in 
6698 individuals aged 45 to 84 years who were asymptomatic 
and free of CVD at baseline. The study found that compared 
with CIMT, CAC was more strongly associated with incident 
CVD in the overall population. In contrast, CIMT was found 
to be a modestly better predictor of stroke than CAC scoring, 
which could be perhaps the result of the difference between 
vascular territories targeted by the two measures.58 Although 
the CAC estimation was a better predictor of incident CVD 
in this study, measurement of CAC has a major disadvantage 
of exposing people to ionizing radiation.
CIMT and cardiovascular  
risk factors
A number of risk factors have been associated with the devel-
opment of atherosclerosis in the carotid arteries. The findings 
that the risk factors that predict CIMT are those that also 
predict coronary artery disease is concordant with the 
evidence that atherosclerosis is a diffuse disease.59 These risk 
factors include increasing age,60–62 male sex,63 smoking,61–64 
blood pressure,61–64 measures of adiposity such as body 
mass index,60,65 waist-to-hip ratio,66 sedentary lifestyle,66 
family history,67 ethnicity,68 and the presence of diabetes or 
glucose intolerance.63,64,66 CIMT has also been reported to be 
associated with serum cholesterol,60–64 triglyceride levels,60 
high-density lipoprotein (HDL) cholesterol,60–64 low-density 
lipoprotein LDL cholesterol,65 high-sensitivity C-reactive 
protein,69 and asymmetric dimethylarginine.70
A number of studies have evaluated the determinants of 
change in CIMT over time.71 The Atherosclerosis Risk in 
Communities (ARIC) study among 15,792 individuals aged 
45 to 64 years reported statistically significant associations 
of change in CIMT with baseline diabetes, current smoking, 
HDL cholesterol, pulse pressure, white blood cell count, and 
fibrinogen during the follow-up from 1987 to 1998.72 Further-
more, significant associations were found between change in 
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and with onset of diabetes and hypertension, during the 
follow-up. Data from the Rotterdam study among 3409 men 
and women aged $55 years, in which CIMT was measured 
twice 6.5 years apart, indicated that moderate to severe 
progression of CIMT (above the 60th and 90th percentile of 
CIMT, respectively) was related to age, body mass index, 
male sex, current smoking, systolic blood pressure, and the 
presence of hypertension.73 Lipid levels, however, were not 
related to increased progression of CIMT. Recently, the 
Carotid Atherosclerosis Progression Study among 3383 men 
and women found that age, male sex, hypertension, presence 
of diabetes, and smoking were related to increased progres-
sion of internal CIMT over 3 years, whereas no relation was 
found for common CIMT.74
These studies suggest that CIMT is increased in the pres-
ence of risk factors associated with CVD and furthermore, 
the progression of CIMT is associated with cardiovascular 
risk factors.
CIMT in people with type 1 diabetes
Several research groups have found an association between 
type 1 diabetes and CIMT.55,57,75–79 Yamasaki and colleagues 
evaluated CIMT to assess the carotid arteries in 105 young 
patients with type 1 diabetes, 529 patients with type 2 diabetes, 
and 104 nondiabetic healthy people subjects. People with 
type 1 diabetes had significantly higher CIMT than healthy 
controls, whereas people with noninsulin-dependent diabetes 
showed CIMT values equivalent to those in normal adults. 
They reported that on multiple regression analysis CIMT in 
insulin-dependent diabetes patients was positively related to 
the duration of diabetes as well as to age. No other possible 
risk factors, such as serum total cholesterol level, serum HDL 
cholesterol level, LDL cholesterol, serum triglycerides, serum 
lipoprotein(a) level, or systolic or diastolic blood pressure 
showed any significant correlations. However, non-HDL 
cholesterol, smoking, and systolic hypertension were inde-
pendently responsible for increases in CIMT values of type 
2 diabetes patients as well as age and duration of diabetes.55 
Larsen and colleagues reported higher CIMT values in people 
with type 1 diabetes. They also reported a significant asso-
ciation between the glycosylated hemoglobin (HbA1c) levels 
and CIMT (r2 = 0.77; P , 0.0001 when adjusted for age) in 
women with type 1 diabetes, though no such correlation was 
seen in men. Among women, a significant association was 
also found between CIMT and the percentage of coronary 
vessel area stenosis, measured by intravascular ultrasound.57 
The Epidemiology of Diabetes Interventions and Com-
plications (EDIC) Research Group found that   traditional 
  cardiovascular risk factors including increasing age, smok-
ing, and LDL cholesterol were related to CIMT.80 In a further 
study, 40 people aged 11 to 30 years with duration of type 1 
diabetes of 3 to 25 years compared with 40 healthy controls 
confirmed a higher CIMT in the cohort with diabetes (0.6 ± 0.1 
vs 0.4 ± 0.1 mm; P , 0.001). CIMT was found to correlate 
with age (r = 0.76; P , 0.001), body mass index (r = 0.82; 
P , 0.001), duration of diabetes (r = 0.66; P , 0.001), systolic 
blood pressure (r = 0.82; P , 0.001), diastolic blood pressure 
(r = 0.83; P , 0.001), HbA1c (r = 0.40; P = 0.004) and HDL 
(r = −0.88; P , 0.001).81
In an observational longitudinal study over a period of 
2.5 years of 102 people with type 1 diabetes, CIMT increased 
by a mean of 0.033 mm per year.82 Furthermore, CIMT was 
found to correlate with age (r = 0.34; P , 0.01), diabetes 
duration (r = 0.25; P , 0.05) and systolic blood pressure 
(r = 0.28; P , 0.05) at baseline. In addition, the maximum 
change in CIMT was observed in people who had hyper-
tension and nephropathy. CIMT has been reported to be 
increased in children with type 1 diabetes compared with 
healthy controls.83,84 Atherogenic risk factors such as systolic 
blood pressure, duration of diabetes, and body weight were 
positively correlated with CIMT in children and adolescents 
with type 1 diabetes.84
In type 1 diabetes, the increase in CIMT has been shown 
to start in childhood and adolescence by some55,75 but not all 
studies.85,86 In a recent study of young children with type 1 
diabetes with modest glycemic control, Margeirsdottir and 
colleagues reported increased CIMT despite intensive 
insulin treatment.86 In another study, Schwab and colleagues 
reported increased CIMT in the pediatric population (body 
mass index), markers of sustained inflammation, endothelial 
dysfunction, and fibrinolytic activity were increased in dia-
betic versus nondiabetic children, none of these measures 
being significant correlates of CIMT. The authors reported 
that that in well-controlled type 1 diabetes, systolic blood 
pressure may be of greater importance than dyslipidemia in 
early atherogenesis.84
In a study of young people with type 1 diabetes without 
known macrovascular disease or microalbuminuria, CIMT 
was found to be increased by 25% (P , 0.001) in type 1 
diabetes compared with healthy controls.22
CIMT in people with impaired 
glucose tolerance and type 2 diabetes
People with impaired glucose tolerance (IGT) have been shown 
to have endothelial dysfunction and are at increased risk of 
CVD. CIMT has been observed to be increased in people Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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who would subsequently develop diabetes.87 Yamasaki and 
colleagues have reported that people with IGT had increased 
CIMT and there was no difference in CIMT among the people 
with IGT and age- and sex-matched people with type 2 dia-
betes.88 In another study postchallenge glucose levels were 
strongly associated with CIMT in people at risk of diabetes or 
who were at the early stages of type 2 diabetes.89 These studies 
suggest that people with IGT or at the early stages of type 2 
diabetes are already at increased risk of CVD.
A review of 21 studies including 24,111 people with type 
2 diabetes (n = 4019) and IGT (n = 1110) found that CIMT 
was higher in individuals with diabetes compared to the 
healthy controls. Compared with healthy controls, CIMT was 
increased in individuals with type 2 diabetes by 0.13 (95% CI: 
0.12–0.14) mm and by 0.04 (95% CI: 0.01–0.07) mm in indi-
viduals with IGT.90 Other research groups have found CIMT 
to be increased in type 2 diabetes.91–93 Furthermore, CIMT has 
been demonstrated to be higher in people with diabetes and 
macrovascular disease.94 In a prospective study, Bernard and 
colleagues reported that CIMT provides a similar predictive 
value for coronary events compared with the Framingham score, 
and suggested that the combination of these two indexes would 
significantly improve risk prediction in these patients.95
A study was conducted in 98 people with type 2 diabetes 
with no known CVD to ascertain the clinical usefulness of 
CIMT in identifying those individuals in whom the single-
photon emission computed tomography myocardial perfusion 
imaging is abnormal.96 An increased CIMT was found to be 
significantly related to the presence and extent of abnormal 
myocardial perfusion. In another study, the usefulness of 
CIMT in predicting the presence of coronary artery disease, 
as detected by noninvasive computed tomographic coronary 
angiography, in asymptomatic people with diabetes was 
investigated (n = 150, aged 50 ± 13 years, 83 men).97 Mean 
CIMT increased from 0.58 ± 0.08 mm in those with normal 
coronary arteries (n = 59, 39%), to 0.67 ± 0.12 mm in those 
with nonobstructive atherosclerosis (n = 54, 36%) and 
0.75 ± 0.12 mm in those with obstructive stenosis defined 
as a $50% narrowing of the luminal diameter (n = 36, 25%; 
P , 0.01). Furthermore, a cut-off value of 0.67 mm for 
CIMT predicted obstructive coronary atherosclerosis with 
a sensitivity of 85% and specificity of 72%.
CIMT has been shown to be a predictor of incidence 
and recurrence of stroke.44,98 Similarily, increased CIMT has 
been found to be associated with increased risk of ischemic 
stroke in people with type 2 diabetes.99,100 Increased CIMT 
and plaque score have been demonstrated to correlate with 
acute ischemic stroke in patients with type 2 diabetes.99
Along with hyperglycemia, other metabolic factors 
  associated with diabetes that are known to increase cardiovas-
cular risk including obesity, insulin resistance, hypertension, 
hyperlipidemia, and increased inflammatory state have all been 
shown to contribute to progression of CIMT in people with 
diabetes.98,99,101,102 The Relationship between Insulin Sensitivity 
and Cardiovascular disease (RISC) study conducted in 1326 
European nondiabetic healthy individuals aged 30 to 60 years 
measured CIMT and its associations with fasting insulin 
and insulin resistance by performing standard oral glucose 
tolerance tests and hyperinsulinemic euglycemic clamps.103 
CIMT was statistically significantly associated with fasting 
insulin in healthy people. In contrast, Kong and colleagues 
studied normotensive individuals with type 2 diabetes and 
found no association between CIMT and fasting insulin or 
insulin sensitivity as assessed with an insulin-modified fre-
quently sampled intravenous glucose tolerance test.104
Thus CIMT is increased in people with diabetes from a 
young age. The progression of CIMT is associated with the 
traditional risk factors of CVD such as hypertension and 
dyslipidemia.
CIMT and microvascular 
complications
CIMT has been shown to be increased in people with type 
1 diabetes and retinopathy.105,106 In a cross-sectional study, 
the severity of retinopathy was found to be associated with 
CIMT (odds ratio per 0.1 mm CIMT 1.09 [95% CI: 1.01–1.17; 
P = 0.01]),107 consistent with studies in people with type 2 
diabetes.108,109 In a recent study, Vigili de Kreutzenberg and 
colleagues studied the association between diabetic retinopa-
thy and CIMT in people with type 2 diabetes. The authors 
reported that retinopathy either alone or in combination with 
nephropathy, is independently associated with CIMT in people 
with type 2 diabetes, and the severity of microangiopathy cor-
relates with severity of carotid atherosclerosis.110 In another 
study of people with type 1 diabetes, the association between 
CIMT and microangiopathic complications including retin-
opathy or nephropathy was reported.111
Effect of therapeutic interventions 
on CIMT in people with diabetes
Blood glucose lowering in type 1  
and type 2 diabetes and CiMT
A 16-week intensive lifestyle modification program and 
subsequent monthly meetings during the 6-month study period 
in 58 people with type 2 diabetes was found to be associated Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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with a significantly reduced mean CIMT   progression 
after 6 months (−0.040 ± 0.136 vs +0.083 ± 0.167 mm; 
P = 0.007).112 Furthermore, changes in HbA1c (r = 0.34; 
P = 0.028), fasting plasma glucose (r = 0.31; P = 0.045), and 
2-hour postprandial plasma glucose (r = 0.37; P = 0.015) 
correlated with the mean CIMT change after adjustment for 
age and sex. Thus, in addition to improved blood glucose 
control, lifestyle measures have decreased progression of 
CIMT. Data analyses from 11 studies (n = 1578) in people 
with type 2 diabetes and IGT evaluated the effect of inter-
ventions on change in CIMT. The annual increase of CIMT 
was 0.034 mm/y (95% CI: 0.029–0.039) in people with type 
2 diabetes without any specific interventions in which mean 
HbA1c was 7.86%. A significant close correlation of HbA1c 
with rate of CIMT change was found (r = 0.35; P = 0.01). 
Agents for lowering of blood glucose, platelet activation, 
or blood pressure significantly reduced the CIMT increase, 
independent of blood glucose control.113
As part of the EDIC study, the long-term follow-up of 
the Diabetes Control and Complications Trial (DCCT), 
1229 people with type 1 diabetes (intensive blood glucose 
lowering arm n = 618; conventional blood glucose lowering 
arm n = 611) underwent internal and common CIMT mea-
surements in 1994 to 1996 and again in 1998 to 2000.56 
Although CIMT was not statistically significantly different 
between the people with diabetes and the healthy controls 
after 1 year of follow-up in the EDIC study,114 CIMT was 
significantly greater in people with type 1 diabetes compared 
with the healthy controls after a follow-up of 6 years in the 
EDIC study.56 Furthermore, the progression of CIMT in the 
common carotid artery was significantly less in the group 
that received intensive therapy than in the group that received 
conventional therapy during the DCCT (0.032 vs 0.046 mm; 
P = 0.01) after adjustment for other risk factors. Factors that 
were associated with progression of CIMT were age, the 
EDIC base-line systolic blood pressure, smoking, ratio of 
LDL to HDL cholesterol, urinary albumin excretion rate, and 
the mean HbA1c during the DCCT.
A Japanese study randomized individuals with type 2 
diabetes without known macrovascular disease to pioglitazone 
with or without other oral glucose-lowering agents (n = 89) 
or other oral glucose-lowering agents excluding thiazolidene-
diones (n = 97), with treatment goal of HbA1c ,6.5%. The 
authors found that pioglitazone induced regression of mean 
CIMT from 0.839 ± 0.1873 to 0.780 ± 0.1571 mm; P = 0.002), 
although the between-group difference did not reach statistical 
significance.115
The Pioglitazone in the Prevention of Diabetes (PIPOD) 
study assessed the effects of pioglitazone in Hispanic women 
with prior gestational diabetes mellitus who had previously 
completed the troglitazone in the Prevention of Diabetes 
(TRIPOD) study.116–118 Thirty-one women came to PIPOD 
from the troglitazone arm while 30 came from the placebo 
arm of TRIPOD. During the 3-year follow-up, the 31 women 
who came to PIPOD from the troglitazone arm of TRIPOD 
were found to have a lower progression of CIMT of 38% 
during pioglitazone treatment than during troglitazone treat-
ment, although this was not statistically significant (0.0037 
vs 0.0060 mm/year; P = 0.260). The progression of CIMT 
was 69% lower during pioglitazone treatment than it had been 
during placebo in the 30 women who came to PIPOD from 
the placebo arm of TRIPOD (0.0031 vs 0.0100 mm/year; 
P = 0.006). The authors concluded that pioglitazone slows 
progression of CIMT in women who had been on placebo in 
the TRIPOD study and maintained a low rate of progression 
in those who had previously been treated with troglitazone. 
The low CIMT progression during treatment with the thiaz-
olidendiones was speculated to be due to PPAR-γ activation 
in the vasculature and change in proinflammatory and pro-
thrombotic markers.119,120
A greater reduction in CIMT independent of improved 
glycemic control, after 12 and 24 weeks of pioglitazone treat-
ment, compared to glimeperide in 173 people with type 2 
diabetes has been reported.121 These data were later confirmed 
by Mazzone and colleagues in 462 people with type 2 diabetes 
(mean age 60 years) during a 72-week study. The authors 
found that the mean change in CIMT was less with piogli-
tazone than with glimepiride (−0.001 mm vs +0.012 mm, 
respectively; difference −0.013 mm; P = 0.020).122
In another study, pioglitazone, but not glibenclamide or 
voglibose, was found to reduce CIMT in people with type 
2 diabetes and diabetic nephropathy at 6- and 12-month 
follow-up.123
In the randomized, placebo-controlled, Study of 
  Atherosclerosis with Ramipril and Rosiglitazone (STARR), 
the effect of ramipril and of rosiglitazone on CIMT in 
people with IGT or impaired fasting glucose (IFG) was 
investigated.124 People with IGT and/or IFG but without CVD 
or diabetes (n = 1425) were randomized to ramipril 15 mg/day 
or its placebo and to rosiglitazone 8 mg/day or its placebo with 
a 2 × 2 factorial design. The annual change of the maximum 
CIMT and the mean common CIMT were measured after 
a median follow-up of 3 years. Rosiglitazone significantly 
reduced the mean CIMT (difference 0.0043 ± 0.0017 mm/y, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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P = 0.010) but not the maximum CIMT. In contrast, there 
was no statistically significant difference between the ramipril 
and placebo groups.
In another study, glibenclamide in combination with 
metformin was associated with reduced progression of CIMT 
(0.003 ± 0.048 mm) compared with glibenclamide alone 
(0.064 ± 0.045 mm) and gliclazide group (0.032 ± 0.036 mm) 
(P , 0.0001 and P = 0.043 respectively).125 The annual 
progression of maximum CIMT in the gliclazide group 
(0.044 ± 0.106 mm) and the glibenclamide plus metformin 
group (0.041 ± 0.105 mm) was smaller than that of the gliben-
clamide group (0.114 ± 0.131 mm). Attenuation of the CIMT 
progression by metformin in people with type 2 diabetes has 
been confirmed by others.126 Metformin has antithrombotic 
effects, modulates the generation of reactive oxygen species, 
and reduces systemic methylglyoxal concentration, all of which 
might contribute to the beneficial effect on CIMT.127,128
The Copenhagen Insulin and Metformin Therapy trial 
aims to assess the effect of an 18-month treatment with 
metformin versus placebo in combination with one of three 
insulin analog regimens, with CIMT being the primary 
outcome measured in 950 individuals with type 2 diabetes. 
The three insulin regimens compared are 1) insulin detemir 
before bedtime (n ∼ 315 patients), 2) biphasic insulin aspart 
30 before dinner with the possibility to increase to 2 or 
4 injections daily (n ∼ 315 patients), and 3) insulin aspart 
before the main meals (three times daily) and insulin detemir 
before bedtime (n ∼ 315 patients).129
In the prospective, randomized, placebo-controlled, 
Study to Prevent Non-Insulin Dependent Diabetes Mellitus 
(STOP-NIDDM) trial, an α-glucosidase inhibitor, acarbose, 
delayed progression from IGT to overt type 2 diabetes and 
reduced cardiovascular events.130 A subgroup analysis of the 
STOP-NIDDM study examined the efficacy of acarbose on 
progression of CIMT in people with IGT.131 One hundred 
thirty-two individuals with IGT were randomized to placebo 
(n = 66) or acarbose (n = 66). After a mean follow-up of 
3.9 years, significant reduction in the progression of CIMT 
was observed in the acarbose group versus placebo. CIMT 
increased by 0.02 ± 0.07 mm in the acarbose group versus 
0.05 ± 0.06 mm in the placebo group (P = 0.027). The annual 
increase of CIMT was reduced by approximately 50% in 
the acarbose group versus placebo. CIMT progression was 
significantly related to acarbose intake on multiple linear 
regression analyses. As the primary effect of acarbose is on 
meal-time hyperglycemia, these data supported the impor-
tance of postprandial hyperglycemia.
A substudy was performed in 175 of 401 individuals 
with type 2 diabetes who had participated in an epidemio-
logical study to assess the relationship between postprandial 
hyperglycemia and surrogate markers of atherosclerosis.132 
The effects of repaglinide (n = 88) and glyburide (n = 87) 
on CIMT were compared after 12 months. Although, HbA1c 
improved to a comparable extent in both groups (−0.9%), 
the postprandial glucose peak was lower in the repaglinide 
group (P , 0.010). CIMT regression, defined as a decrease 
of .0.020 mm, was noted in a greater proportion of people 
on repaglinide (52%) than on glyburide 18% (P , 0.010). 
Furthermore, the reduction in CIMT was associated with 
changes in postprandial but not fasting hyperglycemia. These 
data add to recent research, which suggests that postprandial 
hyperglycemic excursions may be more important than basal 
hyperglycemia in triggering atherosclerosis.
Antihypertensive agents and CiMT  
in people with diabetes
Post-hoc analyses of the association between antihyperten-
sive treatment and CIMT in the Troglitazone Atherosclerosis 
Regression Trial (TART), which assessed CIMT progres-
sion in adults with insulin-treated type 2 diabetes, found 
that higher systolic blood pressure was associated with a 
higher CIMT progression rate (P = 0.03). Furthermore, 
anti-hypertensive treatment reduced this association in a 
duration-dependent manner (interaction P = 0.035).133
Hosomi and colleagues did a prospective randomized 
clinical trial of 98 patients with type 2 diabetes who were 
randomized to either enalapril 10 mg/d (n = 48) or to a con-
trol group (n = 50) for 2 years.134 The enalapril-treated group 
was found to have reduced annual thickening of the common 
carotid arteries by 0.01 ± 0.004 mm/y relative to the control 
group over the course of this study. These data concur with 
other data which showed that angiotensin-converting enzyme 
(ACE) inhibitors led to a reduction in myocardial infarction, 
stroke, cardiovascular death, total mortality, revasculariza-
tion, and overt nephropathy.135 Importantly, the D allele of the 
ACE gene has been shown to be an independent risk factor 
for coronary artery disease and with CIMT in individuals 
with type 2 diabetes.136,137
Lipid-lowering treatment and CiMT  
in people with diabetes
People with type 2 diabetes without prior cardiovascular events 
participated in the Stop Atherosclerosis in Native   Diabetics 
Study (SANDS) trial and were randomized to a   standard Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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group (target LDL cholesterol #2.6 mmol/L; non-HDL 
  cholesterol #3.4 mmol/L; systolic blood pressure #130 mmHg) 
and an aggressive group with tighter targets (target 
LDL cholesterol #1.8 mmol/L; non-HDL cholesterol 
#2.6 mmol/L; systolic blood pressure #115 mmHg), and 
were treated with statins alone or statins plus ezetimibe.138 
The CIMT changes in both aggressive subgroups were com-
pared with changes in the standard subgroups (target LDL 
cholesterol #2.6 mmolL; non-HDL cholesterol #3.4 mmol/L; 
systolic blood pressure #130 mmHg). Within the aggressive 
group, mean CIMT at 36 months regressed from baseline simi-
larly in the ezetimibe (−0.025 mm, range −0.05 to 0.003 mm) 
and nonezetimibe subgroups (−0.012 mm, range −0.03 to 
0.008 mm) but progressed in the standard treatment arm 
(0.039 mm, range 0.02–0.06 mm; intergroup; P , 0.0001). 
The authors concluded that reducing LDL cholesterol to 
aggressive targets resulted in similar regression of CIMT in 
patients who attained equivalent LDL cholesterol reductions 
from a statin alone or statin plus ezetimibe. CIMT increased 
in those achieving standard targets.
The Arterial Biology for the Investigation of the Treatment 
Effects of Reducing Cholesterol 6: HDL and LDL Treatment 
Strategies in Atherosclerosis (ARBITER 6-HALTS) study 
found that niacin resulted in a significant regression of mean 
and maximal CIMT whereas there was no significant change 
in CIMT in the ezetimibe-treated subgroup.139 Although not 
powered for clinical outcomes, there were more major car-
diovascular events in the ezetimibe arm than in the niacin arm 
(9 events vs 2 events, respectively; P = 0.040).
Anti-platelet therapy and CiMT  
in people with diabetes
Kodama and colleagues followed up 150 people aged 52 
to 76 years with type 2 diabetes and without known CVD 
whose baseline CIMT was .1.1 mm.140 Antiplatelet agents 
(aspirin 81 mg/day, n = 40; ticlopidine 200 mg/day, n = 36; 
no drugs n = 74) were administered. Individuals without 
anti-platelet agents had an annual progression of CIMT of 
0.067 mm/y. In contrast, low-dose aspirin or ticlopidine 
attenuated the progression of CIMT by 50% (0.033 mm and 
0.034 mm/year, respectively).
More recently, the prospective, randomized, open-label, 
blinded Diabetic Atherosclerosis Prevention by Cilostazol 
(DAPC) study showed that in people with type 2 diabetes 
suspected of peripheral artery disease, a phosphodiesterase 
inhibitor, cilostazol (100–200 mg/day) caused greater regres-
sion in the maximum and mean CIMT compared with aspirin 
(81–100 mg/day) during a 2-year observation period (mean left 
CIMT −0.043 ± 0.182 vs 0.028 ± 0.202 mm; P = 0.004; 
mean right CIMT −0.024 ± 0.182 vs 0.048 ± 0.169 mm; 
P , 0.001).141
Conclusions
Diabetes is associated with increased cardiovascular and 
cerebrovascular disease-related mortality. Early identification 
of people at higher risk can influence the treatment strategies 
to reduce the morbidity and mortality. CIMT measure-
ment is a relatively easy, noninvasive technique to identify 
atherosclerosis. People with diabetes have higher CIMT than 
the healthy population. CIMT increases in the presence of 
micro- and macrovascular complications of diabetes. Several 
treatment strategies in diabetes which have been shown to 
reduce diabetic complications also cause regression of CIMT. 
Thus, routine measurement of CIMT may add value to risk 
stratification and facilitate better use of various treatment 
strategies in people with diabetes.
Assessment of CIMT provides an excellent opportunity 
to evaluate the atherosclerotic risk in people with diabetes 
and can further be used to facilitate better use of various 
treatment strategies in people with diabetes. Further random-
ized studies would be required to assess the role of CIMT in 
predicting the development of various complications and how 
various available treatment strategies could be incorporated 
to influence the outcome.
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of   diabetes 
on survival following myocardial infarction in men vs women. The 
Framingham Study.  JAMA. 1988;260(23):3456–3460.
2.  Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes 
in a national cohort of the US population, 1971–1993. Diabetes Care. 
1998;21(7):1138–1145.
3.  Savage PJ. Cardiovascular complications of diabetes mellitus: what we 
know and what we need to know about their prevention. Ann Intern Med. 
1996;124(1 Pt 2):123–126.
4.  Webster MW, Scott RS. What cardiologists need to know about diabetes. 
Lancet. 1997;350 Suppl 1:SI23–SI28.
5.  Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk 
factors, and 12-yr cardiovascular mortality for men screened in the 
Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2): 
434–444.
6.  Kannel WB, McGee DL. Diabetes and cardiovascular disease. The 
Framingham study.  JAMA. 1979;241(19):2035–2038.
7.  Jamrozik K, Broadhurst RJ, Forbes S, Hankey GJ, Anderson CS. 
Predictors of death and vascular events in the elderly: the Perth 
Community Stroke Study. Stroke. 2000;31(4):863–868.
8.  Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associa-
tions of fasting insulin, body fat distribution, and diabetes with risk of 
ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study 
Investigators. Diabetes Care. 1999;22(7):1077–1083.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
31
CiMT in diabetes
  9.  Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non-insulin-dependent 
diabetes and its metabolic control are important predictors of stroke in 
elderly subjects. Stroke. 1994;25(6):1157–1164.
  10.  Donahue RP, Orchard TJ. Diabetes mellitus and macrovascular 
complications. An epidemiological perspective. Diabetes Care. 
1992;15(9):1141–1155.
  11.  Maser RE, Wolfson SK Jr. Ellis D, et al. Cardiovascular disease 
and arterial calcification in insulin-dependent diabetes mellitus: 
interrelations and risk factor profiles. Pittsburgh Epidemiology of 
Diabetes Complications Study-V . Arterioscler Thromb. 1991;11(4): 
958–965.
  12.  Orchard TJ, Dorman JS, Maser RE, et al. Prevalence of complications 
in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes 
Complications Study II. Diabetes. 1990;39(9):1116–1124.
  13.  Orchard TJ, Dorman JS, Maser RE, et al. Factors associated with 
avoidance of severe complications after 25 yr of IDDM. Pittsburgh 
Epidemiology of Diabetes Complications Study I. Diabetes Care. 
1990;13(7):741–747.
  14.  You RX, McNeil JJ, O’Malley HM, Davis SM, Thrift AG, Donnan GA. 
Risk factors for stroke due to cerebral infarction in young adults. Stroke. 
1997;28(10):1913–1918.
  15.  Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial 
disease in diabetic and nondiabetic patients: a comparison of severity 
and outcome. Diabetes Care. 2001;24(8):1433–1437.
  16.  Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a 
marker of atherosclerosis in the Cardiovascular Health Study. Cardio-
vascular Heart Study (CHS) Collaborative Research Group. Circulation. 
1993;88(3):837–845.
  17.  Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction 
induced by acetylcholine in atherosclerotic coronary arteries. N Engl J 
Med. 1986;315(17):1046–1051.
  18.  Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial 
function in the human coronary and peripheral circulations. J Am Coll 
Cardiol. 1995;26(5):1235–1241.
  19.  Sorensen KE, Kristensen IB, Celermajer DS. Atherosclerosis in the 
human brachial artery. J Am Coll Cardiol. 1997;29(2):318–322.
  20.  Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive 
detection of endothelial dysfunction in children and adults at risk of 
  atherosclerosis. Lancet. 1992;340(8828):1111–1115.
  21.  Juonala M, Viikari JS, Laitinen T, et al. Interrelations between brachial 
endothelial function and carotid intima-media thickness in young adults: 
the cardiovascular risk in young Finns study. Circulation. 2004;110(18): 
2918–2923.
  22.  Sibal L, Aldibbiat A, Agarwal SC, et al. Circulating endothelial pro-
genitor cells, endothelial function, carotid intima-media thickness 
and circulating markers of endothelial dysfunction in people with 
type 1 diabetes without macrovascular disease or microalbuminuria. 
  Diabetologia. 2009;52(8):1464–1473.
  23.  Ravikumar R, Deepa R, Shanthirani C, Mohan V . Comparison of carotid 
intima-media thickness, arterial stiffness, and brachial artery flow 
mediated dilatation in diabetic and nondiabetic subjects (The Chennai 
Urban Population Study [CUPS-9]). Am J Cardiol. 2002;90(7): 
702–707.
  24.  Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-
media thickness consensus (2004–2006). An update on behalf of the 
Advisory Board of the 3rd and 4th Watching the Risk Symposium, 
13th and 15th European Stroke Conferences, Mannheim, Germany, 
2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007;23(1): 
75–80.
  25.  Jacoby DS, Mohler IE, Rader DJ. Noninvasive atherosclerosis imaging 
for predicting cardiovascular events and assessing therapeutic interven-
tions. Curr Atheroscler Rep. 2004;6(1):20–26.
  26.  O’Leary DH, Bots ML. Imaging of atherosclerosis: carotid intima-media 
thickness. Eur Heart J. 2010;31(14):1682–1689.
  27.  Mukherjee D, Yadav JS. Carotid artery intimal-medial thickness: indica-
tor of atherosclerotic burden and response to risk factor modification. 
Am Heart J. 2002;144(5):753–759.
  28.  Iglesias del Sol A, Bots ML, Grobbee DE, Hofman A, Witteman JC. 
Carotid intima-media thickness at different sites: relation to incident 
myocardial infarction; The Rotterdam Study. Eur Heart J. 2002;23(12): 
934–940.
  29.  Gepner AD, Korcarz CE, Aeschlimann SE, et al. Validation of a carotid 
intima-media thickness border detection program for use in an office 
setting. J Am Soc Echocardiogr. 2006;19(2):223–228.
  30.  Bots ML, Baldassarre D, Simon A, et al. Carotid intima-media thickness 
and coronary atherosclerosis: weak or strong relations? Eur Heart J. 
2007;28(4):398–406.
  31.  Gamble G, Beaumont B, Smith H, et al. B-mode ultrasound images 
of the carotid artery wall: correlation of ultrasound with histological 
measurements. Atherosclerosis. 1993;102(2):163–173.
  32.  Graf S, Gariepy J, Massonneau M, et al. Experimental and clinical 
validation of arterial diameter waveform and intimal media thickness 
obtained from B-mode ultrasound image processing. Ultrasound Med 
Biol. 1999;25(9):1353–1363.
  33.  Wong M, Edelstein J, Wollman J, Bond MG. Ultrasonic-pathological 
comparison of the human arterial wall. Verification of intima-media 
thickness. Arterioscler Thromb. 1993;13(4):482–486.
  34.  Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial 
thickness of the arterial wall: a direct measurement with ultrasound 
imaging. Circulation. 1986;74(6):1399–1406.
  35.  Grobbee DE, Bots ML. Carotid artery intima-media thickness 
as an indicator of generalized atherosclerosis. J Intern Med. 
1994;236(5):567–573.
  36.  Yamakado M, Fukuda I, Kiyose H. Ultrasonographically assessed 
carotid intima-media thickness and risk for asymptomatic cerebral 
infarction. J Med Syst. 1998;22(1):15–18.
  37.  Bots ML, Dijk JM, Oren A, Grobbee DE. Carotid intima-media 
thickness, arterial stiffness and risk of cardiovascular disease: current 
evidence. J Hypertens. 2002;20(12):2317–2325.
  38.  Oren A, Vos LE, Uiterwaal CS, Grobbee DE, Bots ML. Cardiovascular 
risk factors and increased carotid intima-media thickness in healthy 
young adults: the Atherosclerosis Risk in Young Adults (ARYA) Study. 
Arch Intern Med. 2003;163(15):1787–1792.
  39.  Crouse JR 3rd, Tang R, Espeland MA, Terry JG, Morgan T, Mercuri M. 
Associations of extracranial carotid atherosclerosis progression with 
coronary status and risk factors in patients with and without coronary 
artery disease. Circulation. 2002;106(16):2061–2066.
  40.  Espeland MA, Craven TE, Riley WA, Corson J, Romont A, 
  Furberg CD. Reliability of longitudinal ultrasonographic measure-
ments of carotid intimal-medial thicknesses. Asymptomatic Carotid 
Artery Progression Study Research Group. Stroke. 1996;27(3): 
480–485.
  41.  Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. 
  Common carotid intima-media thickness and risk of stroke and 
myocardial infarction: the Rotterdam Study. Circulation. 1997;96(5): 
1432–1437.
  42.  Burke GL, Evans GW, Riley WA, et al. Arterial wall thickness is 
associated with prevalent cardiovascular disease in middle-aged adults. 
The Atherosclerosis Risk in Communities (ARIC) Study. Stroke. 1995; 
26(3):386–391.
  43.  Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness 
is predictive of incident clinical stroke: the Atherosclerosis Risk in 
Communities (ARIC) study. Am J Epidemiol. 2000;151(5):478–487.
  44.  O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, 
Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor 
for myocardial infarction and stroke in older adults. Cardiovascular 
Health Study Collaborative Research Group. N Engl J Med. 1999; 
340(1):14–22.
  45.  Holme I, Enger SC, Helgeland A, et al. Risk factors and raised athero-
sclerotic lesions in coronary and cerebral arteries. Statistical analysis 
from the Oslo study. Arteriosclerosis. 1981;1(4):250–256.
  46.  Mitchell JR, Schwartz CJ. Relationship between arterial disease in 
different sites. A study of the aorta and coronary, carotid, and iliac 
arteries. Br Med J. 1962;1(5288):1293–1301.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
32
Sibal et al
  47.  Craven TE, Ryu JE, Espeland MA, et al. Evaluation of the associations 
between carotid artery atherosclerosis and coronary artery stenosis. 
A case-control study. Circulation. 1990;82(4):1230–1242.
  48.  Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-
media thickness in predicting clinical coronary events. Ann Intern Med. 
1998;128(4):262–269.
  49.  Dawson JD, Sonka M, Blecha MB, Lin W, Davis PH. Risk factors 
associated with aortic and carotid intima-media thickness in adolescents 
and young adults: the Muscatine Offspring Study. J Am Coll Cardiol. 
2009;53(24):2273–2279.
  50.  Lorenz MW, von Kegler S, Steinmetz H, Markus HS, Sitzer M. Carotid 
intima-media thickening indicates a higher vascular risk across a wide 
age range: prospective data from the Carotid Atherosclerosis Progres-
sion Study (CAPS). Stroke. 2006;37(1):87–92.
  51.  Cao JJ, Arnold AM, Manolio TA, et al. Association of carotid artery 
intima-media thickness, plaques, and C-reactive protein with future 
cardiovascular disease and all-cause mortality: the Cardiovascular 
Health Study. Circulation. 2007;116(1):32–38.
  52.  Johnson HM, Douglas PS, Srinivasan SR, et al. Predictors of carotid 
intima-media thickness progression in young adults: the Bogalusa Heart 
Study. Stroke. 2007;38(3):900–905.
  53.  Liu L, Zhao F, Yang Y, et al. The clinical significance of carotid intima-
media thickness in cardiovascular diseases: a survey in Beijing. J Hum 
Hypertens. 2008;22(4):259–265.
  54.  Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M.   Prediction 
of clinical cardiovascular events with carotid intima-media 
thickness: a systematic review and meta-analysis. Circulation. 2007; 
115(4):459–467.
  55.  Yamasaki Y, Kawamori R, Matsushima H, et al. Atherosclerosis in 
carotid artery of young IDDM patients monitored by ultrasound high-
resolution B-mode imaging. Diabetes. 1994;43(5):634–639.
  56.  Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and 
carotid intima-media thickness in type 1 diabetes mellitus. N Engl J 
Med. 2003;348(23):2294–2303.
  57.  Larsen JR, Brekke M, Bergengen L, et al. Mean HbA1c over 18 years 
predicts carotid intima media thickness in women with type 1 diabetes. 
Diabetologia. 2005;48(4):776–779.
  58.  Folsom AR, Kronmal RA, Detrano RC, et al. Coronary artery 
calcification compared with carotid intima-media thickness in the 
prediction of cardiovascular disease incidence: the Multi-Ethnic 
Study of Atherosclerosis (MESA). Arch Intern Med. 2008;168(12): 
1333–1339.
  59.  Mancini GB, Dahlof B, Diez J. Surrogate markers for cardiovascular 
disease: structural markers. Circulation. 2004;109(25 Suppl 1): 
IV22–IV30.
  60.  Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial 
thickness is related to cardiovascular risk factors measured from 
childhood through middle age: The Muscatine Study. Circulation. 
2001;104(23):2815–2819.
  61.  Bonithon-Kopp C, Scarabin PY, Taquet A, Touboul PJ, Malmejac A, 
Guize L. Risk factors for early carotid atherosclerosis in middle-aged 
French women. Arterioscler Thromb. 1991;11(4):966–972.
  62.  Ferrieres J, Elias A, Ruidavets JB, et al. Carotid intima-media thick-
ness and coronary heart disease risk factors in a low-risk population. 
J Hypertens. 1999;17(6):743–748.
  63.  Mannami T, Konishi M, Baba S, Nishi N, Terao A. Prevalence of 
asymptomatic carotid atherosclerotic lesions detected by high-  resolution 
ultrasonography and its relation to cardiovascular risk factors in the 
general population of a Japanese city: the Suita study. Stroke. 1997; 
28(3):518–525.
  64.  Kuller L, Borhani N, Furberg C, et al. Prevalence of subclinical 
atherosclerosis and cardiovascular disease and association with 
risk factors in the Cardiovascular Health Study. Am J Epidemiol. 
1994;139(12):1164–1179.
  65.  Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors 
and carotid vascular changes in adulthood: the Bogalusa Heart Study.   
JAMA. 2003;290(17):2271–2276.
  66.  Folsom AR, Eckfeldt JH, Weitzman S, et al. Relation of carotid artery 
wall thickness to diabetes mellitus, fasting glucose and insulin, body 
size, and physical activity. Atherosclerosis Risk in Communities (ARIC) 
Study Investigators. Stroke. 1994;25(1):66–73.
  67.  Bensen JT, Li R, Hutchinson RG, Province MA, Tyroler HA. Family 
history of coronary heart disease and pre-clinical carotid artery 
atherosclerosis in African-Americans and whites: the ARIC study: 
Atherosclerosis Risk in Communities. Genet Epidemiol. 1999;16(2): 
165–178.
  68.  Li R, Duncan BB, Metcalf PA, et al. B-mode-detected carotid artery 
plaque in a general population. Atherosclerosis Risk in Communities 
(ARIC) Study Investigators. Stroke. 1994;25(12):2377–2383.
  69.  Wang TJ, Nam BH, Wilson PW, et al. Association of C-reactive protein 
with carotid atherosclerosis in men and women: the Framingham Heart 
Study. Arterioscler Thromb Vasc Biol. 2002;22(10):1662–1667.
  70.  Ayer JG, Harmer JA, Nakhla S, et al. HDL-cholesterol, blood pres-
sure, and asymmetric dimethylarginine are significantly associated 
with arterial wall thickness in children. Arterioscler Thromb Vasc Biol. 
2009;29(6):943–949.
  71.  Zureik M, Touboul PJ, Bonithon-Kopp C, et al. Cross-sectional and 
4-year longitudinal associations between brachial pulse pressure and 
common carotid intima-media thickness in a general population. 
The EVA study. Stroke. 1999;30(3):550–555.
  72.  Chambless LE, Folsom AR, Davis V , et al. Risk factors for progression of 
common carotid atherosclerosis: the Atherosclerosis Risk in Communities 
Study, 1987–1998. Am J Epidemiol. 2002;155(1):38–47.
  73.  Van der Meer IM, Iglesias del Sol A, Hak AE, Bots ML, Hofman A, 
Witteman JC. Risk factors for progression of atherosclerosis measured 
at multiple sites in the arterial tree: the Rotterdam Study. Stroke. 
2003;34(10):2374–2379.
  74.  Mackinnon AD, Jerrard-Dunne P, Sitzer M, Buehler A, von Kegler S, 
Markus HS. Rates and determinants of site-specific progression of 
carotid artery intima-media thickness: the carotid atherosclerosis pro-
gression study. Stroke. 2004;35(9):2150–2154.
  75.  Jarvisalo MJ, Putto-Laurila A, Jartti L, et al. Carotid artery 
intima-media thickness in children with type 1 diabetes. Diabetes. 
2002;51(2):493–498.
  76.  Frost D, Beischer W. Determinants of carotid artery wall thickening 
in young patients with Type 1 diabetes mellitus. Diabet Med. 
1998;15(10):851–857.
  77.  Mohan V, Ravikumar R, Shanthi Rani S, Deepa R. Intimal medial 
thickness of the carotid artery in South Indian diabetic and non-diabetic 
subjects: the Chennai Urban Population Study (CUPS). Diabetologia. 
2000;43(4):494–499.
  78.  Peppa-Patrikiou M, Scordili M, Antoniou A, Giannaki M, Dracopoulou M, 
Dacou-Voutetakis C. Carotid atherosclerosis in adolescents and young 
adults with IDDM. Relation to urinary endothelin, albumin, free cortisol, 
and other factors. Diabetes Care. 1998;21(6):1004–1007.
  79.  Yokoyama H, Yoshitake E, Otani T, et al. Carotid atherosclerosis in 
young-aged IDDM associated with diabetic retinopathy and diastolic 
blood pressure. Diabetes Res Clin Pract. 1993;21(2–3):155–159.
  80.  Epidemiology of Diabetes Interventions and Complications (EDIC) 
Research Group. Effect of intensive diabetes treatment on carotid 
artery wall thickness in the epidemiology of diabetes interventions and 
complications. Diabetes. 1999;48(2):383–390.
  81.  Abdelghaffar S, El Amir M, El Hadidi A, El Mougi F. Carotid intima-
media thickness: an index for subclinical atherosclerosis in type 1 
diabetes. J Trop Pediatr. 2006;52(1):39–45.
  82.  Frost D, Friedl A, Beischer W. Determinants of early carotid athero-
sclerosis progression in young patients with type 1 diabetes mellitus. 
Exp Clin Endocrinol Diabetes. 2002;110(2):92–94.
  83.  Rabago Rodriguez R, Gomez-Diaz RA, Tanus Haj J, et al. Carotid 
intima-media thickness in pediatric type 1 diabetic patients. Diabetes 
Care. 2007;30(10):2599–2602.
  84.  Schwab KO, Doerfer J, Krebs A, et al. Early atherosclerosis in childhood 
type 1 diabetes: role of raised systolic blood pressure in the absence of 
dyslipidaemia. Eur J Pediatr. 2007;166(6):541–548.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
33
CiMT in diabetes
  85.  Singh TP, Groehn H, Kazmers A. Vascular function and carotid 
intimal-medial thickness in children with insulin-dependent diabetes 
mellitus. J Am Coll Cardiol. 2003;41(4):661–665.
  86.  Margeirsdottir HD, Stensaeth KH, Larsen JR, Brunborg C, 
Dahl-Jorgensen K. Early signs of atherosclerosis in diabetic children 
on intensive insulin treatment: a population-based study. Diabetes 
Care. 33(9):2043–2048.
  87.  Hunt KJ, Williams K, Rivera D, et al. Elevated carotid artery intima-
media thickness levels in individuals who subsequently develop 
type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003;23(10): 
1845–1850.
  88.  Yamasaki Y, Kawamori R, Matsushima H, et al. Asymptomatic hyper-
glycaemia is associated with increased intimal plus medial thickness 
of the carotid artery. Diabetologia. 1995;38(5):585–591.
  89.  Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, 
Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic 
spikes are more strongly associated with atherosclerosis than 
fasting glucose or HbA1c level. Diabetes Care. 2000;23(12): 
1830–1834.
  90.  Brohall G, Oden A, Fagerberg B. Carotid artery intima-media thick-
ness in patients with Type 2 diabetes mellitus and impaired glucose 
tolerance: a systematic review. Diabet Med. 2006;23(6):609–616.
  91.  Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Uusitupa 
M. Carotid artery intima-media thickness in elderly patients with NIDDM 
and in nondiabetic subjects. Stroke. 1996;27(11):1986–1992.
  92.  Temelkova-Kurktschiev TS, Koehler C, Leonhardt W, et al. Increased 
intimal-medial thickness in newly detected type 2 diabetes: risk factors. 
Diabetes Care. 1999;22(2):333–338.
  93.  Wagenknecht LE, D’Agostino RB Jr. Haffner SM, Savage PJ, 
Rewers M. Impaired glucose tolerance, type 2 diabetes, and carotid 
wall thickness: the Insulin Resistance Atherosclerosis Study. Diabetes 
Care. 1998;21(11):1812–1818.
  94.  Lee CD, Folsom AR, Pankow JS, Brancati FL. Cardiovascular events 
in diabetic and nondiabetic adults with or without history of myocardial 
infarction. Circulation. 2004;109(7):855–860.
  95.  Bernard S, Serusclat A, Targe F, et al. Incremental predictive value 
of carotid ultrasonography in the assessment of coronary risk in a 
cohort of asymptomatic type 2 diabetic subjects. Diabetes Care. 
2005;28(5):1158–1162.
  96.  Djaberi R, Schuijf JD, Jukema JW, et al. Increased carotid intima-
media thickness as a predictor of the presence and extent of 
abnormal myocardial perfusion in type 2 diabetes. Diabetes Care. 
2010;33(2):372–374.
  97.  Djaberi R, Schuijf JD, de Koning EJ, et al. Usefulness of carotid 
intima-media thickness in patients with diabetes mellitus as a 
predictor of coronary artery disease. Am J Cardiol. 2009;104(8): 
1041–1046.
  98.  Li C, Engstrom G, Berglund G, Janzon L, Hedblad B. Incidence of 
ischemic stroke in relation to asymptomatic carotid artery atheroscle-
rosis in subjects with normal blood pressure. A prospective cohort 
study. Cerebrovasc Dis. 2008;26(3):297–303.
  99.  Lee EJ, Kim HJ, Bae JM, et al. Relevance of common carotid intima-
media thickness and carotid plaque as risk factors for ischemic stroke 
in patients with type 2 diabetes mellitus. AJNR Am J Neuroradiol. 
2007;28(5):916–919.
  100.  Matsumoto K, Sera Y, Nakamura H, Ueki Y, Miyake S. Correlation 
between common carotid arterial wall thickness and ischemic 
stroke in patients with type 2 diabetes mellitus. Metabolism. 2002; 
51(2):244–247.
  101.  Davis TM, Millns H, Stratton IM, Holman RR, Turner RC. Risk 
factors for stroke in type 2 diabetes mellitus: United Kingdom 
Prospective Diabetes Study (UKPDS) 29. Arch Intern Med. 
1999;159(10):1097–1103.
  102.  Urbina EM, Kimball TR, McCoy CE, Khoury PR, Daniels SR, 
Dolan LM. Youth with obesity and obesity-related type 2 diabetes 
mellitus demonstrate abnormalities in carotid structure and function. 
Circulation. 2009;119(22):2913–2919.
 103.  De Rooij SR, Dekker JM, Kozakova M, et al. Fasting insulin has a stronger 
association with an adverse cardiometabolic risk profile than insulin 
resistance: the RISC study. Eur J Endocrinol. 2009;161(2):223–230.
  104.  Kong C, Elatrozy T, Anyaoku V , Robinson S, Richmond W, Elkeles RS. 
Insulin resistance, cardiovascular risk factors and ultrasonically mea-
sured early arterial disease in normotensive Type 2 diabetic subjects. 
Diabetes Metab Res Rev. 2000;16(6):448–453.
  105.  Distiller LA, Joffe BI, Melville V , Welman T, Distiller GB. Carotid 
artery intima-media complex thickening in patients with relatively 
long-surviving type 1 diabetes mellitus. J Diabetes Complications. 
2006;20(5):280–284.
  106.  Glowinska-Olszewska B, Urban M, Urban B, Tolwinska J, 
Szadkowska A. The association of early atherosclerosis and retinopathy 
in adolescents with type 1 diabetes: preliminary report. Acta Diabetol. 
2007;44(3):131–137.
  107.  Klein R, Sharrett AR, Klein BE, et al. The association of atherosclerosis, 
vascular risk factors, and retinopathy in adults with diabetes : the 
atherosclerosis risk in communities study. Ophthalmology. 2002;109(7): 
1225–1234.
  108.  Malecki MT, Osmenda G, Walus-Miarka M, et al. Retinopathy 
in type 2 diabetes mellitus is associated with increased intima-
media thickness and endothelial dysfunction. Eur J Clin Invest. 
2008;38(12):925–930.
  109.  Rema M, Mohan V , Deepa R, Ravikumar R. Association of carotid 
intima-media thickness and arterial stiffness with diabetic retinopathy: 
the Chennai Urban Rural Epidemiology Study (CURES-2). Diabetes 
Care. 2004;27(8):1962–1967.
  110.  Vigili de Kreutzenberg S, Coracina A, Volpi A, et al. Microangiopathy 
is independently associated with presence, severity and composition 
of carotid atherosclerosis in type 2 diabetes. Nutr Metab Cardiovasc 
Dis. 2010 Feb 15. [Epub ahead of print].
  111.  Gul K, Ustun I, Aydin Y, et al. Carotid intima-media thickness and 
its relations with the complications in patients with type 1 diabetes 
mellitus. Anadolu Kardiyol Derg. 10(1):52–58.
  112.  Kim SH, Lee SJ, Kang ES, et al. Effects of lifestyle modification on 
metabolic parameters and carotid intima-media thickness in patients 
with type 2 diabetes mellitus. Metabolism. 2006;55(8):1053–1059.
  113.  Yokoyama H, Katakami N, Yamasaki Y. Recent advances of interven-
tion to inhibit progression of carotid intima-media thickness in patients 
with type 2 diabetes mellitus. Stroke. 2006;37(9):2420–2427.
  114.  Epidemiology of Diabetes Interventions and Complications (EDIC) 
Research Group. Effect of intensive diabetes treatment on carotid 
artery wall thickness in the epidemiology of diabetes interventions 
and complications. Diabetes. 1999;48(2):383–390.
  115.  Yamasaki Y, Katakami N, Furukado S, et al. Long-Term Effects of 
Pioglitazone on Carotid Atherosclerosis in Japanese Patients with 
Type 2 Diabetes without a Recent History of Macrovascular Morbidity. 
J Atheroscler Thromb. 2010.
  116.  Xiang AH, Peters RK, Kjos SL, et al. Effect of thiazolidinedione 
treatment on progression of subclinical atherosclerosis in premeno-
pausal women at high risk for type 2 diabetes. J Clin Endocrinol 
Metab. 2005;90(4):1986–1991.
  117.  Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. 
TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, 
placebo-controlled trial of troglitazone in women with prior gestational 
diabetes mellitus. Control Clin Trials. 1998;19(2):217–231.
  118.  Xiang AH, Hodis HN, Kawakubo M, et al. Effect of pioglitazone 
on progression of subclinical atherosclerosis in non-diabetic 
premenopausal Hispanic women with prior gestational diabetes. 
Atherosclerosis. 2008;199(1):207–214.
  119.  Hsueh WA, Law RE. PPARgamma and atherosclerosis: effects 
on cell growth and movement. Arterioscler Thromb Vasc Biol. 
2001;21(12):1891–1895.
  120.  Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone 
on blood concentrations of plasminogen activator inhibitor 1 in patients 
with type 2 diabetes and in lean and obese normal subjects. Diabetes. 
2000;49(4):633–639.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is 
an international, peer-reviewed open-access journal committed to 
the rapid publication of the latest laboratory and clinical findings 
in the fields of diabetes, metabolic syndrome and obesity research.   
Original research, review, case reports, hypothesis formation, expert 
opinion and commentaries are all considered for publication. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
34
Sibal et al
  121.  Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases 
carotid intima-media thickness independently of glycemic control 
in patients with type 2 diabetes mellitus: results from a controlled 
randomized study. Circulation. 2005;111(19):2525–2531.
  122.  Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone 
compared with glimepiride on carotid intima-media thickness in type 2 
diabetes: a randomized trial.  JAMA. 2006;296(21):2572–2581.
  123.  Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on 
carotid intima-media thickness and arterial stiffness in type 2 diabetic 
nephropathy patients. Metabolism. 2004;53(10):1382–1386.
  124.  Lonn EM, Gerstein HC, Sheridan P, et al. Effect of ramipril and 
of rosiglitazone on carotid intima-media thickness in people with 
impaired glucose tolerance or impaired fasting glucose: STARR 
(STudy of Atherosclerosis with Ramipril and Rosiglitazone). J Am 
Coll Cardiol. 2009;53(22):2028–2035.
  125.  Katakami N, Yamasaki Y, Hayaishi-Okano R, et al. Metformin or 
gliclazide, rather than glibenclamide, attenuate progression of carotid 
intima-media thickness in subjects with type 2 diabetes. Diabetologia. 
2004;47(11):1906–1913.
  126.  Matsumoto K, Sera Y, Abe Y, Tominaga T, Yeki Y, Miyake S. 
Metformin attenuates progression of carotid arterial wall thick-
ness in patients with type 2 diabetes. Diabetes Res Clin Pract. 
2004;64(3):225–228.
  127.  Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk 
factors for cardiovascular disease, and plasminogen activator inhibitor 
in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 
1993;16(4):621–629.
  128.  Bonnefont-Rousselot D, Raji B, Walrand S, et al. An intracellular 
modulation of free radical production could contribute to the 
beneficial effects of metformin towards oxidative stress. Metabolism. 
2003;52(5):586–589.
  129.  Lundby Christensen L, Almdal T, Boesgaard T, et al. Study rationale 
and design of the CIMT trial: the Copenhagen Insulin and Metformin 
Therapy trial. Diabetes Obes Metab. 2009;11(4):315–322.
  130.  Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. 
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM 
randomised trial. Lancet. 2002;359(9323):2072–2077.
  131.  Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, 
  Temelkova-Kurktschiev T. Acarbose slows progression of intima-
media thickness of the carotid arteries in subjects with impaired 
glucose tolerance. Stroke. 2004;35(5):1073–1078.
  132.  Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid 
atherosclerosis by control of postprandial hyperglycemia in type 2 
diabetes mellitus. Circulation. 2004;110(2):214–219.
  133.  Zheng L, Hodis HN, Buchanan TA, Li Y, Mack WJ. Effect of 
antihypertensive therapy on progression of carotid intima-media 
thickness in patients with type 2 diabetes mellitus. Am J Cardiol. 
2007;99(7):956–960.
  134.  Hosomi N, Mizushige K, Ohyama H, et al. Angiotensin-converting 
enzyme inhibition with enalapril slows progressive intima-media 
thickening of the common carotid artery in patients with non-insulin-
dependent diabetes mellitus. Stroke. 2001;32(7):1539–1545.
  135.  Heart Outcomes Prevention Evaluation Study Investigators. Effects 
of ramipril on cardiovascular and microvascular outcomes in people 
with diabetes mellitus: results of the HOPE study and MICRO-HOPE 
substudy. Lancet. 2000;355(9200):253–259.
  136.  Hosoi M, Nishizawa Y, Kogawa K, et al. Angiotensin-converting 
enzyme gene polymorphism is associated with carotid arterial wall 
thickness in non-insulin-dependent diabetic patients. Circulation. 
1996;94(4):704–707.
  137.  Ruiz J, Blanche H, Cohen N, et al. Insertion/deletion polymorphism 
of the angiotensin-converting enzyme gene is strongly associated with 
coronary heart disease in non-insulin-dependent diabetes mellitus. 
Proc Natl Acad Sci U S A. 1994;91(9):3662–3665.
  138.  Fleg JL, Mete M, Howard BV , et al. Effect of statins alone versus 
statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: 
the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. 
J Am Coll Cardiol. 2008;52(25):2198–2205.
  139.  Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin 
or ezetimibe and carotid intima-media thickness. N Engl J Med. 
2009;361(22):2113–2122.
  140.  Kodama M, Yamasaki Y, Sakamoto K, et al. Antiplatelet drugs attenuate 
progression of carotid intima-media thickness in subjects with type 2 
diabetes. Thromb Res. 2000;97(4):239–245.
  141.  Katakami N, Kim YS, Kawamori R, Yamasaki Y. The phosphodi-
esterase inhibitor cilostazol induces regression of carotid atheroscle-
rosis in subjects with type 2 diabetes mellitus: principal results of the 
Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: 
a randomized trial. Circulation. 2010;121(23):2584–2591.